Fig. 2

Effects of ProEGCG and EGCG on cell proliferation of human endometrial cancer cells. RL95–2 and AN3 CA cells were treated with increasing doses of (a, b) EGCG (20, 40, and 60 μM) and (c, d) ProEGCG (20, 40, and 60 μM) for 24, 48 and 72 h. Cell viability was assessed by MTT assay. The percentage of viable cells was calculated as the ratio of the number of treated cells to the number of control cells. Data are presented as mean ± S.E.M. Significant differences from control: *P < 0.05 and **P < 0.01